Xanthic Biopharma Inc. President, Gary Galitsky and Board Member, Dr. Gunther Hintz, advance cannabis opportunity in Thailand

Thursday, April 26, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

TORONTO, April 26, 2018 /CNW/ - Xanthic Biopharma Inc. (formerly Aurquest Resources Inc.) ("Xanthic" or the "Company")

is pleased to announce two of its executives, President Gary Galitsky, and Director Dr. Gunther Hintz, made a presentation on April 25, 2018 at a cannabis conference
hosted by Bangkok's Kasetsart University, Thailand's largest university. The theme of the conference was to educate and teach the benefits of cannabinoid-based medicine, the history of herbal use and the future state of cannabis in the world.

Attendees included the Thai Minister of Health, Director of Drug Enforcement, Justice Minister, Minister of Agriculture, Pharmacological Head of Thailand and over 200 invited attendees, comprised of Thai doctors, pharmacists and medical practitioners. Xanthic was invited to participate in this event by Dr Samnouk, of iMed Therapy Co., Ltd., one of the leading biotechnology companies in Thailand, acting as a key consultant to the Thai government. Thailand has a population of 69 million and is the second largest economy in South East Asia.

Mr. Galitsky and Dr. Hintz presented an overview of Canadian cannabis legal history and the current Canadian legal landscape. Thailand is currently evaluating the decriminalization of cannabis and is looking at Canada as a "best-in-class" source for lessons and best practices.

In addition, Mr. Galitsky and Dr. Hintz introduced the audience to the Xanthic Biopharma patent-pending technology and the benefits of the Xanthic water-soluble THC and CBD product line.

Said Mr. Galitsky: "We are honoured to have been invited to speak at this conference. It is a great opportunity to have some involvement in the evolution of legal change in Thailand and to showcase the benefits of the Xanthic water soluble products. Although it is early days, we look forward to a time when we could create partnerships in Asia to expand the Xanthic footprint."

About Xanthic Xanthic, through its wholly-owned operating subsidiary, Xanthic Biopharma Limited, provides valuable intellectual property to cannabis industry participants, enabling its strategic partners to produce high quality, innovative, non-combustible cannabis, and cannabis-infused products which deliver consistent THC and/or CBD levels. Using a proprietary patent-pending process, Xanthic allows its strategic partners to deliver superior cannabinoid solubility, accurate micro-dosing, faster onset, increased bioavailability and improved consistency versus competitive infused products.

Through its investment in Avitas CBD Water, Xanthic has access to non-cannabis derived CBD infused products that qualify for distribution outside of the Cannabis dispensary network and into mainstream retail.

SOURCE Xanthic BioPharma

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store